Sonora Investment Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 13.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 176,373 shares of the biopharmaceutical company’s stock after purchasing an additional 21,194 shares during the period. Pfizer accounts for approximately 0.9% of Sonora Investment Management LLC’s portfolio, making the stock its 19th largest holding. Sonora Investment Management LLC’s holdings in Pfizer were worth $7,640,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Evolution Wealth Advisors LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $34,000. Winch Advisory Services LLC lifted its stake in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 336 shares during the period. Ruggie Capital Group purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $44,000. Karp Capital Management Corp purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $53,000. Finally, HMS Capital Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $71,000. 71.82% of the stock is currently owned by institutional investors.
In other news, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares of the company’s stock, valued at $3,524,136. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the completion of the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.
PFE has been the topic of several recent analyst reports. Barclays reissued a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Morgan Stanley lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $48.00 to $40.00 in a research report on Tuesday. JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, July 29th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Finally, Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday. Fifteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $46.44.
PFE stock traded down $0.25 on Friday, hitting $38.00. 27,652,919 shares of the company were exchanged, compared to its average volume of 25,745,708. Pfizer Inc. has a twelve month low of $37.68 and a twelve month high of $46.47. The company has a fifty day simple moving average of $42.85. The firm has a market cap of $215.95 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 3.08 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 27.57%. The company had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.8 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.79%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: How mutual funds make money
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.